PharmDr. et ThDr. et Mgr. Aleš FRANC, Ph.D., Th.D.

 

Education and academic qualifications

  • 2014: ThDr. in Hussite Theology, Hussite Theological Faculty, Charles University in Prague
  • 2014: Th.D. in Hussite Theology, Hussite Theological Faculty, Charles University in Prague
  • 2012: Mgr. in Evangelical Theology, Matej Bel University, Banska Bystrica
  • 2010: Ph.D. in Pharmaceutical Technology, University of Veterinary and Pharmaceutical Sciences Brno
  • 2009: Mgr. in Hussite Theology, Hussite Theological Faculty, Charles University in Prague
  • 2007: Bc. in Evangelical Theology and Missiology, Matej Bel University, Banska Bystrica
  • 2004: PharmDr. in Pharmaceutical Technology, University of Veterinary and Pharmaceutical Sciences Brno
  • 1994: Attestation in Technological Pharmacy, ILF Prague
  • 1990: Mgr. in Technological Pharmacy and General Pharmacy, Faculty of Pharmacy, Charles University in Prague

 

Professional experience

  • 2010 – Assistant Professor, University of Veterinary and Pharmaceutical Sciences Brno
  • 1992 – 2009: Scientific Researcher, Pliva – Barr, Brno
  • 1990 - 1991: Pharmaceutical Assistant, Pharmaceutical Service, Prachatice

 

Teaching activities

  • Master course of pharmacy: lecturer - Medical forms and Biopharmacy. Tutor of diploma and rigorous thesises, postgraduate students supervisor in Pharmaceutical Technology.
  • Master course of pharmacy: lecturer - Medical forms and galenics, Tutor of postgraduate students.(UVLF Košice)

 

Research activities

  • Preparation of dosage forms with poorly soluble and hardly absorbable APIs; formulation of dosage forms with controlled release, direct compression of tablets with low content of APIs.

 

Professional stays abroad

  • 2002-2008: Transfers of pharmaceutical technologies to Pliva Zagreb (Croatia), Zydus and Emcure (India), Elaiapharm (France)
  • 1999: Coating School, Colorcon, Dartford, UK

 

 

Other academic activities, research projects, grants

  • 55/2014/FaF Tvorba biorelevantní disoluční metody pro kontrolu kvality tablet s obsahem warfarinu. University of Veterinary and Pharmaceutical Sciences Brno.
  • 61/2014/FaF Vývoj pH závislé disoluční metody pro kontrolu uvolňování glukosy z pelet s řízeným uvolňováním pro prevenci hypoglykémie. University of Veterinary and Pharmaceutical Sciences Brno.
  • 14479/2013, Preparation of dosage forms with controlled release of glucose to prevention of hypoglycemic states. Ministry of Health of the Czech Republic.
  • 39 /2011/FaF Safety increasing of oral solid dosage drugs with narrow therapeutic index. University of Veterinary and Pharmaceutical Sciences Brno.
  • FB-CV/09/2000,  Léčiva k prevenci a léčbě virových onemocnění a nemocí centrálního nervového systému. MPO.
  • PZ - Z2/29, Nová léčiva pro terapii nádorových onemocnění. MPO.

 

Non-university activities

  • Czech Pharmaceutical Society  –  The Section of Drug Technology, Scientific Secretary (since 2011)
  • European Industrial Pharmacists Group – (since 2009)

 

Major publications

            Selected Articles

  • MUSELÍK, J., FRANC A., DOLEŽEL, P., GONĚC, R., KRONDLOVÁ, A., LUKÁŠOVÁ, I.: Influence of process parameters on content uniformity of a low dose active pharmaceutical ingredient in a tablet formulation according to GMP. Acta. Pharm. 2014 (64), 355-367. IF2014 = 1.025.
  • MATEJOVA, I., MODRA, H., BLAHOVA, J., FRANC, A., FICTUM, P., SEVCIKOVA, M.,  SVOBODOVA, Z.: The Effect of mycotoxin deoxynivalenol on haematological and biochemical indicators and histopathological changes in Rainbow Trout (Oncorhynchus mykiss)  Int. J. Pharm. Biomed. Res. 2014, (2014), Article ID 310680. IF2014 = 2.706.
  • VETCHÝ, D., KOPECKÁ, M., VETCHÁ, M. FRANC, A.: In vitro - in vivo models in drug development. Chem. Listy. 2014 (108), 32-39. IF2014= 0,196
  • DVOŘÁČKOVÁ, K., FRANC, A., KEJDUŠOVÁ, M.: Targeting of drugs into colon. Chem. Listy. 2013 (107), 522-529. IF2013= 0.196
  • DOBŠÍKOVÁ, R., BLAHOVÁ, J, FRANC, A., JAKUBÍK, J., MIKULÍKOVÁ, I., MODRÁ, H., NOVOTNÁ, K. SVOBODOVÁ, Z.: Effect of β-1.3/1.6-d-glucan derived from oyster mushroom pleurotus ostreatus on biomedical, haematological, biochemical, and immunological indices in rainbow trout (oncorhynchus mykiss). Neuroendocrinol. Lett. 2012 (33). IF2011= 1.296
  • FRANC, A., VETCHÝ, D., SMILKOVÁ, L., RABIŠKOVÁ, M., KRATOCHVÍL, B.: Lipophilic formulations for increasing bioavailability of poorly water-soluble drugs. Chem. Listy. 2012 (106), 3-9. IF2011= 0.529
  • OKÁČOVÁ, L., VETCHÝ, D., FRANC, A., RABIŠKOVÁ, M.: Increasing bioavailability of poorly water-soluble drugs by technological methods facilitating drug dissolution. Chem. Listy. 2011 (105), 34-40. IF2011= 0.529
  • OKÁČOVÁ, L., VETCHÝ, D., FRANC, A., RABIŠKOVÁ, M. KRATOCHVÍL, B.: Increasing bioavailability of poorly water-soluble drugs by their modification. Chem. Listy. 2010 (104), 21-26. IF2010 = 0.620
  • CHLADEK, J., ZALUDEK, B., SOVA, P., FRANC, A., SISPERA, L., MARTINKOVA, J., MICUDA, S.,  CERMANOVA, J.: Steady-state bioequivalence studies of two memantine tablet and oral solution formulations in healthy volunteers. J. Appl. Biomeb. 2008 (6), 39-45. IF2008-13 = 1.964
  • CHLÁDEK, J., ŠIŠPERA L., MARTINKOVÁ, J., ŽALUDEK, B., SOVA, P., MIČUDA, S., GRIM, J., CERMANOVÁ, J., FRANC, A.: Bioequivalence of two rimantadine tablet formulation in healthy male volunteers after single dose administrativ. Int. J. Clin. Pharmacol. Ther. 2001 (39), 179-184. IF2001= 1.350

 

            Selected Patents

  • SOVA, P., KROUTIL, A., FRANC, A. Polymorphic form (iii ) of the adamantylamino- platinum (iv) complex La- 12. PLIVA LACHEMA AS [CZ] WO2009100691; 2009-08-20
  • FRANC A., GONEC R., ŽALUDEK, B. Solid oral dosage form containing bicalutamide and method of preparation. PLIVA HRVASTKA [HR] WO2008099160; 2008-08-21
  • FRANC, A., SOVA, P. Pharmaceutical composition for oral administration. PLIVA LACHEMA AS [CZ] AU2007262493; 2007-12-27
  • FRANC, A., ŽALUDEK B., et. al. Preparation and composition of a solid dosage form containing tacrolimus and/or sirolimus. Inventor:  PLIVA ISTRAZIVANJE I RAZVOJ D [HR] WO2007091059; 2007-08-16
  • FRANC, A., SOVA, P. Oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, method for producing and use as medicament thereof. PLIVA LACHEMA AS [CZ] EP1802295; 2007-07-04
  • FRANC, A., SOVA, P. Pharmaceutical composition for injectional, particularly targeted local administration. PLIVA LACHEMA AS [CZ] AU2007262496 ; 2007-12-27
  • FRANC, A., SOVA, P. Pharmaceutical composition for administration by injection. PLIVA LACHEMA AS [CZ] AU2007262494; 2007-12-27
  • FRANC, A., SOVA, P.Pharmaceutical composition for rectal or vaginal application comprising a platinum complex. EP1809274; 2007-07-25
  • FRANC, A., ŽALUDEK, B. Pharmaceutical composition containing ribavirin as active substance and method of manufacturing thereof. PLIVA LACHEMA AS [CZ] EP1617824; 2006-01-2.
  • FRANC, A., ŽALUDEK, B. Oral solid instant-release dosage forms comprising finasteride and an anionic surfactant - methods of manufacturing thereof.  PLIVA LACHEMA AS [CZ] EP1694336; 2006-08-30
  • FRANC, A., ŽALUDEK B., et. al.   Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component. PLIVA LACHEMA AS [CZ] WO2005034919; 2005-04-21